Lipella Pharmaceuticals Inc. developed therapies using liposomal drug delivery technology and advanced multiple drug candidates into clinical trials, including Phase 2 studies in hemorrhagic cystitis and oral lichen planus.
In June 2026, Lipella's clinical development programs, intellectual property, and regulatory assets were acquired through Chapter 11 proceedings for continued development.
© 2026 Lipella Pharmaceuticals Inc.